Invention:
This invention includes natural compounds for therapeutic use in patients suffering from Alzheimer’s Disease. The inventors have applied computational approaches to existing rich data sets generated by the Accelerating Medical Partnership-Alzheimer's disease consortia to discover novel targets. There are natural compounds which have shown beneficial effects in neuronal and microglial cell cultures. They are validated to protect neurons from cell death and unregulated microglia phagocytic activity.
Background:
Alzheimer’s disease (AD) is the most common form of dementia estimated to affect 36 million people worldwide and an estimated 115 million people by 2050. Alzheimer’s is the sixth leading cause of death in the United States and the fifth leading cause of death among Americans aged 65 and older. Between 2000 and 2018, deaths resulting from stroke, HIV and heart disease decreased, whereas reported deaths from Alzheimer's increased 146.2%. While doctors still don’t know the cause of AD, treatments for the degenerative disease are in high demand.
Applications:
- Treatment of Alzheimer’s disease
- Treatment of other neurological diseases
Advantages:
- Natural compounds
- Protect neurons from cell death
